Cancer name Glioblastoma
Cancer Type GBM
Immunotherapy type Adoptive Cell Therapy
Treatment IL-2
Drugstatus Investigational
Drugbank ID DB14865
Checkpoints NA
Signature Type Gene
Signature Bcl-2
Official Symbol NA
Mode of action TRAN_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Mouse model
Description mRNA expression levels of the apoptosis?inhibiting genes Bcl?w and Bcl?2 were significantly decreased in cells transfected with rAd-p53 compared with controls .
PMID 29328445
Title The effects of interleukin 2 and rAd-p54 as a treatment for glioblastoma